Find Academic Supervisors

Eric A. RossView profile

Research Professor

• Biostatistics
• Bioinformatics
• Clinical Trial Design
• +7 more

Eric A. Ross is a Research Professor and Assistant Vice President of Biometrics and Information Sciences at Fox Chase Cancer Center, where he directs both the Biostatistics and Bioinformatics Facility and the Population Studies Facility within the Cancer Prevention and Control program. He holds a PhD in Statistics from Temple University, an ScM in Biostatistics from Johns Hopkins University, and a BA in Biological Sciences from the University of Delaware. His research interests include biostatistics, bioinformatics, clinical trial design, cancer research, and health informatics. He specializes in developing innovative statistical methodologies for oncology trials and integrating large-scale data using web-based technologies to improve cancer research and patient outcomes. His recent publications highlight a strong focus on clinical trial methodology, molecular oncology, and data integration. Key themes include risk-adapted therapies for bladder cancer, confounding control in clinical studies, and reproductive factors in breast cancer. His work often involves multicenter collaborations and leverages genomic and epidemiological data to identify biomarkers and optimize treatment strategies. Dr. Ross is a member of the American Statistical Association and the International Biometrics Society. His scientific contributions are reflected in over 200 peer-reviewed publications, with recent work appearing in high-impact journals such as Journal of Clinical Oncology , Annals of Internal Medicine , and Clinical Cancer Research . He leads a multidisciplinary team providing biostatistical and informatics support across clinical, translational, and basic science research at Fox Chase. His lab emphasizes improving research efficiency, data quality, and the application of advanced computational tools in cancer investigations. He has collaborated extensively with researchers in urology, oncology, and epidemiology, contributing to significant advances in personalized cancer therapy and data-driven decision making.

Annemarie Leliveld-KorsView profile

Researcher

• Urology
• Oncology
• Nephrology
• +4 more

Dr. Annemarie Leliveld-Kors is a Urologist at the Faculty of Medical Sciences , University of Groningen, specializing in Urology , Oncology , and Nephrology with a focus on sustainability in healthcare . Her work bridges clinical urology and environmental impact reduction. Faculty of Medical Sciences, University of Groningen UMC Groningen (Hanzeplein and Broerstraat locations) Research Interests span bladder cancer , prostate cancer , polycystic kidney disease , and sustainable medical practices . Recent projects include eco-friendly urology protocols , intravesical chemotherapy , and genetic kidney disorder management . Publication Trends highlight her commitment to clinical trials and healthcare sustainability , with studies on radical cystectomy , pre-transplant nephrectomy , and quality of life metrics in urological and nephrological contexts. Supervision includes co-supervising PhD student J. Falke (2020). Collaborations extend across European institutions like the European Dialysis and Transplant Association and ERA Genes & Kidney Working Group .

• Biomedical Engineering
• Nanotechnology
• Robotics
• +4 more

Samuel Sánchez Ordóñez is an ICREA Research Professor and Group Leader at the Institute for Bioengineering of Catalonia (IBEC), with additional roles as Honorary Visiting Professor at HIT Harbin (China) and Adjunct Professor at POSTECH (South Korea). His academic career spans institutions in Germany, Japan, and Spain, including Max Planck Institute for Intelligent Systems and IFW Dresden. His research focuses on self-propelled nanomotors for biomedical applications, 3D bioprinting of biohybrid actuators , and enzyme-powered microsystems . Key areas include antimicrobial resistance, cancer therapy, and biocompatible nanodevices. Recent publications analyze swarm dynamics of enzymatic nanomotors, electrical stimulation in biohybrid machines , and pluronic-assisted bioprinting for muscle tissue engineering. Awards highlight his status as a leading innovator in nanobiotechnology. Scientific Awards & Grants: ERC Consolidator Grant (2019) Bank Sabadell Foundation Award (2025) MIT TR35 Spain (2014) Guinness World Records (2010, 2017)

Rosalia ViterboView profile

Professor

• Urologic Oncology
• Robotic Surgery
• Minimally Invasive Surgery
• +5 more

Rosalia Viterbo, MD, FACS, is a Professor in the Department of Urology at Fox Chase Cancer Center (Temple University Health System). She specializes in robotic and minimally invasive surgery for urologic cancers, including prostate, bladder, kidney, and adrenal malignancies. With over 1,500 robotic procedures performed, her clinical focus integrates innovative technology with patient-centered care. Education: Fellowship in Robotic Urologic Oncology, City of Hope National Medical Center Residency in General Surgery and Urology, Temple University Hospital MD, State University of New York at Buffalo School of Medicine (2000) Research Focus: Dr. Viterbo leads studies on prostate cancer therapeutics, robotic surgical techniques for cystectomy/nephrectomy, and diagnostic advancements in urologic oncology. Her work emphasizes risk-stratified treatment protocols and quality-of-life outcomes in cancer survivors. Awards & Honors: Fellow, American College of Surgeons (FACS) Philadelphia Magazine Top Doctor (2024, 2025) She maintains active membership in the Society of Urologic Oncology, American Urological Association, and Philadelphia Urological Society.

• Cancer and Oncology
• Urothelial Carcinoma
• Prostate Cancer
• +4 more

Anders Ullén is an Adjunct Professor at the Department of Oncology-Pathology , Karolinska Institutet, with a primary clinical role as Senior Physician at the Pelvic Cancer Unit , Karolinska University Hospital. His work bridges clinical oncology and translational research, focusing on urothelial carcinoma and prostate cancer . University : Karolinska Institutet Department : Oncology-Pathology Academic Rank : Adjunct Professor Role : Senior Physician, Pelvic Cancer Unit Research Interests: Urothelial Carcinoma : Molecular subtypes, treatment outcomes, and prognostic factors. Prostate Cancer : Circulating tumor DNA, response to chemotherapy, and metastatic disease. Clinical Trials : Involvement in trials like JAVELIN Bladder 100 and ProBio. Radiation Therapy : Stereotactic body radiation for metastatic urothelial cancer. Health-related Quality of Life : Long-term outcomes post-cancer treatment. Biomarker Development : Exosome profiling and circulating tumor DNA analysis. Recent publications highlight his focus on molecular subtypes in urothelial cancer, immunotherapy (e.g., pembrolizumab, avelumab), and chemotherapy efficacy in metastatic settings. Collaborative work includes population-based studies in Sweden and Nordic cancer guideline development.

Antonio CarboneView profile

Professor

• Urological Oncology
• Robotic Surgery
• Pelvic Floor Rehabilitation
• +4 more

Antonio Carbone serves as a Full Professor in the Department of Medical-Surgical Sciences and Biotechnologies at Sapienza University of Rome's School of Medicine. His academic appointments include teaching roles in Physiotherapy, Medicine and Surgery, and Nursing programs, with specific courses focused on urological rehabilitation, integrated medical-surgical pathology, and clinical nursing in surgical areas. His research spans urological oncology, robotic surgery, and pelvic floor disorders, with significant contributions to prostate and bladder cancer management. Key research areas include: Robotic-assisted surgical techniques for prostatectomy and cystectomy Microbiota interactions in bladder cancer pathogenesis Pelvic floor rehabilitation for sexual dysfunction Medical device safety and imaging diagnostics in urology His publication analysis reveals strong emphasis on multicenter clinical trials evaluating surgical outcomes, with recent work examining environmental impacts of robotic surgery and novel biomarker development for renal cell carcinoma. Notable methodological approaches include pharmacovigilance database analyses and advanced imaging quality assessments. Professional activities demonstrate extensive collaboration through multicenter studies across Italy, with teaching responsibilities spanning undergraduate medical, nursing, and physiotherapy programs. His clinical focus integrates surgical innovation with patient-centered outcome assessment.

Richard LeeView profile

Professor

• Urology
• Male Circumcision
• Bladder Cancer
• +4 more

Richard Lee is a Professor of Population Health Sciences and Urology at Weill Cornell Medical College . He also holds the Nanette Laitman Clinical Scholar title in Population Health Sciences from 2020–2022. MBA, Wharton School of Business, University of Pennsylvania (2003) MD, University of Pennsylvania School of Medicine (2003) BS, Duke University (1998) His research focuses on urology training programs , male circumcision devices , bladder cancer outcomes , and lower urinary tract symptoms . Key areas include surgical education, global health initiatives, and clinical decision-making in prostate and bladder diseases. Recent publications analyze trends in residency training , penile microbiome differences between circumcision methods, and gender disparities in surgical experience . These works span clinical education , surgical technique comparison , and prognostic biomarker analysis . Richard Lee has received grants for urology standardization projects (2023–2026) and male circumcision infrastructure in sub-Saharan Africa (2019–2026) from organizations like the Bill & Melinda Gates Foundation and American Urological Association . He maintains professional relationships with pharmaceutical companies (Johnson & Johnson, Merck, Pfizer) and medical institutions through speaking engagements and educational collaborations.

• Molecular toxicology
• Environmental exposures and neurodegenerative diseases
• Bladder cancer biomarkers
• +5 more

Dr. Angeline S. Andrew serves as Associate Professor of Neurology at the Geisel School of Medicine, Dartmouth College, with additional affiliations in the Dartmouth Cancer Center, Program in Experimental and Molecular Medicine, and Quantitative Biomedical Sciences. Her laboratory operates at the intersection of molecular toxicology and population health sciences. Her educational background includes a PhD from Dartmouth Medical School (2001) where she worked in the Superfund Basic Research Program studying toxic metals mechanisms, and a BS from Tufts University (1996) with double majors in Biology and Environmental Science. Postdoctoral training in molecular epidemiology at the University of Michigan School of Public Health provided expertise in research design and statistical analysis. Dr. Andrew's research program uniquely bridges wet-lab molecular biology with population epidemiology, focusing on how environmental exposures translate to human disease outcomes. Her work examines molecular mechanisms of toxic metals while simultaneously investigating their population-level health impacts, particularly regarding neurodegenerative diseases and cancer progression. Current projects employ advanced techniques including high-throughput molecular analysis, GIS exposure assessment, and statistical modeling of complex gene-environment interactions. Analysis of her publication record reveals a clear trajectory from fundamental molecular toxicology toward population-based environmental health research. Early work focused on nickel and arsenic mechanisms in cell culture, evolving to population studies examining mercury-ALS connections and microRNA biomarkers in bladder cancer. Her research consistently demonstrates translational impact, connecting molecular pathways to clinical outcomes through sophisticated epidemiological approaches. Dr. Andrew maintains an active grant portfolio with multiple NIH and CDC-funded projects, including as PI on the R21CA182659 grant studying dysregulated microRNA in bladder cancer, and as Co-I on several ALS-related studies examining environmental risk factors. She directs the Molecular Biologic Markers in Human Health studies course and teaches Cancer Biology, Epidemiology I, and serves as small group leader for Epidemiology and Biostatistics courses. Her computational and wet-lab expertise supports the SYNERGY Advanced Certificate in Clinical Translational Research program. Her laboratory develops and applies integrated methodologies spanning molecular characterization, exposure assessment, and clinical follow-up. Current projects involve GIS mapping of environmental exposures, high-throughput molecular analysis in R, and longitudinal cohort studies examining how environmental stressors interact with genetic factors to influence disease progression in ALS and bladder cancer.

• Computational Biology
• Medical Physics
• Oncology
• +5 more

Mathias Weyland is a researcher at the Zurich University of Applied Sciences (ZHAW) School of Engineering, specializing in the Applied Complex Systems Science research focus. His work bridges computational modeling, medical physics, and oncology through interdisciplinary projects. Projects : Deputy project leader for Bio-HhOST (bio-hybrid tissue models), PHARAO (pandemic response), and SARS-CoV2 Intervention Modeling , among others. Research Interests : He focuses on computational biology, medical physics, and hyperthermia applications in cancer therapy. His work includes: 3D tissue engineering with live/artificial cell integration Thermoradiation synergy in veterinary oncology Artificial life and droplet-based programmable chemistries Radiation dose optimization for diagnostic imaging Mathematical modeling of biological repair dynamics Publication Trends : His recent work (2024-2020) spans CT scan optimization, thermoradiation effects, and droplet-based artificial life systems. Collaborative projects with institutions like MIT Press, Springer, and Springer Nature dominate his publication record. Methodology : Combines phantom studies, Monte Carlo simulations, and RNA sequencing with a strong emphasis on computational modeling for medical applications.

Maxwell MengView profile

Professor

• Urologic Oncology
• Robotic Surgery
• Minimally Invasive Surgery
• +7 more

Dr. Maxwell Meng is a distinguished academic urologic surgeon at the University of California, San Francisco (UCSF), affiliated with the Department of Urology in the School of Medicine. He specializes in urologic cancers, minimally invasive and robotic surgery, and is actively engaged in developing new treatment technologies. Education: Bachelor of Arts (A), Biochemical Sciences, Harvard College, 1991 Doctor of Medicine (MD), Johns Hopkins School of Medicine, 1995 General Surgery & Urology Residency, UCSF, 1995–2001 Laparoscopic Fellowship, UCSF, 2001–2002 Oncology Fellowship, UCSF, 2002–2003 Dr. Meng’s research spans urologic oncology, with focus on renal cell carcinoma, bladder cancer, and prostate cancer. His work integrates clinical innovation, molecular profiling, immunology, and health services research, particularly examining health disparities and quality of life. He has led and contributed to pivotal clinical trials, including the EVEREST trial on adjuvant everolimus. His recent publications demonstrate a strong trend toward translational research, combining advanced imaging (e.g., 68Ga-FAP PET), immune profiling, and real-world data analysis. Themes include treatment optimization, surgical outcomes, and patient-centered care. Scientific Awards and Honors: Westinghouse Science Talent Search, 7th Place (1987) Magna cum laude, Harvard College (1991) Alpha Omega Alpha, Johns Hopkins (1995) Third Prize, Northern California Urology Residents Seminar (1999) Pfizer Scholar in Urology (2001) Joseph F. McCarthy Essay Contest, 3rd Place, Western Section AUA (2002) Prostate Cancer Research Fellow (2004) William R. Smart Distinguished Teaching Award (selected by residents) (2005) Excellence in Direct Teaching, Academy of Medical Educators, UCSF (2006) Ambrose/Reed Socioeconomic Prize Essay (AUA) (2006) AUA Leadership Program (1 of 16 selected nationally biennially) (2006) Miley B. Wesson Essay Contest, 2nd Place, AUA Dr. Meng is a dedicated educator and mentor, recognized for excellence in teaching by residents and peers. He has been involved in national leadership initiatives and contributes to shaping urologic oncology education and policy. Although specific grant details are not listed, his participation in multicenter trials like SWOG S0931 indicates substantial research funding and collaborative leadership. He is actively involved in multidisciplinary research teams, including those focused on cancer immunology, health economics, and molecular diagnostics. His collaborations span institutions and specialties, reflecting a comprehensive, team-based approach to advancing urologic cancer care.

Matthew I. MilowskyView profile

Professor

• Genitourinary Oncology
• Bladder Cancer
• Prostate Cancer
• +6 more

Matthew I. Milowsky, MD, FASCO is The George Gabriel and Frances Gable Villere Distinguished Professor of Bladder and Genitourinary Cancer Research at the University of North Carolina at Chapel Hill School of Medicine. He serves as Section Chief of the Genitourinary Oncology Service, Co-Director of the Urologic Oncology Program, and Co-Leader of the UNC Lineberger Clinical Research Program. As a medical oncologist and clinical and translational researcher, Dr. Milowsky specializes in the treatment of patients with genitourinary cancers including bladder, testicular, kidney and prostate cancer. Dr. Milowsky's primary research focus is on developing novel therapies for patients with urologic malignancies. He has particular expertise in designing clinical trials that utilize novel immunotherapies and integrated genomics approaches to characterize genitourinary cancers for genetic alterations that may represent targets for novel agents. His work has significantly advanced treatment options for patients with bladder cancer and other urothelial malignancies, with numerous clinical trials evaluating new drug combinations and treatment sequences. Analysis of his recent publications reveals a strong emphasis on immunotherapy approaches for urothelial carcinoma, particularly with agents like nivolumab, enfortumab vedotin, and pembrolizumab. His research spans from early-phase clinical trials to large randomized studies and treatment guidelines, demonstrating leadership in establishing evidence-based practices in genitourinary oncology. The trend in his work shows increasing focus on combination therapies, biomarker-driven treatment selection, and management of treatment-related adverse events. Dr. Milowsky has received numerous prestigious awards including Fellow of the American Society of Clinical Oncology (2021), multiple 'Top Doctor' designations from Castle Connolly, and the AACR Henry Shepard Bladder Cancer Research Award (2009). His consistent recognition as a top physician reflects both his clinical excellence and research contributions to the field. As an educator, Dr. Milowsky has received multiple teaching awards including the Weill Cornell Medical College Hematology and Medical Oncology Faculty Teaching Award (2005) and The MSKCC Paul Sherlock Housestaff Teaching Award (2007). He has been involved in numerous clinical trials funded by the National Institutes of Health, Department of Defense, and pharmaceutical companies, advancing the standard of care for patients with genitourinary cancers. Dr. Milowsky leads the Multidisciplinary Urologic Oncology Clinic at UNC, where patients receive coordinated care from surgeons, radiation oncologists, and medical oncologists during a single visit. His clinical practice and research are deeply integrated, allowing rapid translation of scientific discoveries into improved patient outcomes for those with bladder and other genitourinary cancers.

Andrew WinerView profile

Associate Professor

• Urologic Oncology
• Robotic Surgery
• Health Disparities
• +3 more

Andrew Winer, MD, FACS is Associate Professor of Urology at SUNY Downstate Health Sciences University, serving as Residency Program Director for Urology, Clinical Assistant Dean of Students, and Chief of Urology at Kings County Hospital Center. He also directs Robotic Surgery at Kings County, focusing on urologic malignancies in underserved populations where healthcare disparities significantly impact cancer outcomes. His educational background includes: Doctor of Medicine, SUNY Stony Brook School of Medicine (2005-2009) B.S. Microbiology and Cell Science, University of Florida (2001-2005) Urology Residency, SUNY Downstate (2010-2014) Urologic Oncology Fellowship, Memorial Sloan Kettering Cancer Center (2014-2016) Dr. Winer's research centers on urologic oncology disparities , with emphasis on bladder cancer (radical cystectomy outcomes, upper tract urothelial carcinoma), renal cancer (partial nephrectomy, genomic biomarkers), and prostate cancer in high-risk inner-city populations. His work uniquely bridges robotic surgical innovation with analysis of healthcare access barriers in marginalized communities, revealing critical gaps in cancer representation literature. Analysis of his 15 most recent publications (2015-2018) shows dominant focus on surgical oncology (73%), particularly bladder/renal procedures, with 40% directly addressing underserved populations. Key trends include lymph node yield as a quality metric, genomic characterization of renal tumors, and real-world impacts of screening guideline changes on high-risk patients. As Residency Program Director and Clinical Assistant Dean, Dr. Winer mentors medical students and residents through structured training programs while leading Kings County's urology department. His robotic surgery program advances minimally invasive cancer treatment in resource-limited settings, directly addressing the care disparities that motivated his return to Brooklyn after fellowship.

James M. McKiernanView profile

Professor

• Urologic Oncology
• Bladder Cancer
• Kidney Cancer
• +5 more

James M. McKiernan, MD, serves as the John K. Lattimer Professor of Urology at Columbia University's Vagelos College of Physicians and Surgeons, concurrently holding the positions of Senior Vice Dean for Clinical Affairs and CEO of ColumbiaDoctors. His clinical practice spans multiple NewYork-Presbyterian Hospital affiliates including the Columbia University Irving Medical Center, where he specializes in high-risk urologic oncology cases with emphasis on bladder and kidney cancers. Dr. McKiernan's academic foundation includes: Bachelor of Arts in Biology from Johns Hopkins University Doctor of Medicine from Columbia University College of Physicians and Surgeons Urology and General Surgery Residency at NewYork-Presbyterian Hospital/Columbia University Medical Center Urologic Surgical Oncology Fellowship at Memorial Sloan-Kettering Cancer Center His research program focuses on developing novel bladder cancer therapeutics and comparative effectiveness analysis in urologic oncology. For over a decade, he has directed Columbia's research team investigating surgical quality outcomes while leading an NIH-funded clinical trials program exploring bladder preservation strategies for recurrent cancer patients. Collaborations with the Herbert Irving Comprehensive Cancer Center drive innovation in therapeutic approaches. Professional leadership includes Vice Chairmanship of the AJCC TNM Staging Task Force and Co-Chairmanship of the AUA Guidelines Panel for non-muscle invasive bladder cancer, alongside service on the American Board of Urology and Society of Urologic Oncology Examination Committees. Dr. McKiernan evaluates over 1,000 bladder cancer patients annually, applying expertise in organ-sparing reconstructive surgery to maximize quality of life. His clinical specialties encompass adrenal, kidney, prostate, and testicular cancers with particular focus on major bladder reconstruction techniques.

• Urology
• Oncology
• Medical Imaging
• +4 more

Syed Rahman is a Lecturer at the Department of Urology within Yale School of Medicine . His research focuses on Urology , Oncology , and Medical Imaging , with a particular emphasis on surgical outcomes, diagnostic techniques, and clinical research in prostate and bladder cancer. He collaborates extensively with researchers such as Michael S. Leapman , Preston C. Sprenkle , and David G. Hesse . His recent publications analyze topics like urinary incontinence prediction post-prostate surgery , non-muscle invasive bladder cancer treatment protocols , and survival modeling in oncology . He has contributed to journals including Journal of Endourology , Current Oncology Reports , and Journal of Urology . His work often integrates MRI-ultrasound fusion technology and biostatistical simulations . Dr. Rahman’s clinical research spans radical prostatectomy outcomes in elderly patients , 5-alpha-reductase inhibitor effects on PSA density , and nocturia in heart failure populations . He also explores medical education trends and interdisciplinary applications of technology in urology.

• Prostate Cancer
• Bladder Cancer
• Cancer Stem Cells
• +5 more

Professor Rakesh Heer is affiliated with Newcastle University and actively contributes to prostate and bladder cancer research. His work focuses on molecular mechanisms, stem cell dynamics, and translational approaches. Academic Rank: Professor Research Themes: Prostate Cancer, Bladder Cancer, Cancer Stem Cells, Induced Pluripotent Stem Cells (iPSCs), Androgen Receptor Signaling, Glycosylation Pathways Recent publications highlight his exploration of glycobiology in prostate cancer immunity (e.g., ST3Gal1 and ST6GAL1 roles) and AI applications in bladder cancer recurrence prediction. He also investigates OXPHOS defects , prostate organoids , and clinical trial methodologies for castration-resistant prostate cancer. Professor Heer collaborates extensively on iPSC-based cancer models and urological surgical techniques , including photodynamic diagnosis and focal therapy. His work bridges fundamental molecular biology, translational research, and clinical practice.